59 results about "Controlled release drug" patented technology

The invention discloses a method for in vitro slow release performance evaluation of a slow and controlled release preparation based on the overflow principle. A container with an upper outlet and a lower outlet is adopted to serve as a release tank, a to-be-detected medicine and a dissolution medium are placed in the release tank, a stirring device is adopted in the release tank to perform stirring, and the dissolution medium is added from the lower outlet of the release tank through a peristaltic pump; the dissolution medium dissolved with the medicine is taken away through the overflow from the upper outlet so as to offset medicine absorption or metabolism, and the slow and controlled release speed of the medicine, the total medicine overflow quantity and the total release amount are calculated by measuring the concentration of the medicine contained in the dissolution medium flowing out, the volume of the release tank and the overflow quantity. According to the method, the releasing degree of the slow and controlled release medicine can be evaluated accurately, the effective medicine release time of the slow and controlled release preparation is evaluated, and slow release performances of the slow and controlled release preparation are evaluated comprehensively.

Described herein are compositions, systems, and methods for targeted and controlled drug release. In some embodiments, the compositions, systems, and methods may comprise magnetoelectric silica nanoparticles for targeted and controlled release of chemotherapeutic drugs for cancer treatment. In some embodiments, an external magnetic field may be used to release one or more drugs from the magnetoelectric silica nanoparticles. The disclosed compositions, systems, and methods may improve drug targeting and reduce systemic drug toxicity.

The invention relates to the technical field of medicines, and discloses pedunculoside temperature-sensitive injectable hydrogel as well as a preparation method and application thereof. Specifically, the invention provides application of the temperature-sensitive injectable hydrogel with the pedunculoside in preparation of the medicine for treating the cardiovascular diseases, and the temperature-sensitive injectable hydrogel with the pedunculoside comprises the pedunculoside, a lactic acid-glycolic acid copolymer, polyvinyl alcohol and dipolylactic acid-glycolic acid copolymer polyethylene glycol. The microsphere-gel combined delivery preparation PE-M / Ge prepared by the preparation method disclosed by the invention is good in injectability and has a good temperature-sensitive gelling characteristic in vitro; the obvious gel property is realized, and the microspheres are uniformly distributed in the gel; the release of the drug can be effectively reduced, the release curve is closer to zero-order release, the dual controlled release system can more stably release the drug, the toxic and side effects caused by non-characteristic distribution of PE are reduced, and the bioavailability is improved. And the PE-M / Ge has no cytotoxicity to H9c2 cells and HUVECs cells, so that a foundation is laid for in-vivo pharmacodynamic experiments of rats.

The invention discloses a liver-targeted exosome polydopamine silicon nano drug delivery system as well as a preparation method and application thereof, and relates to the field of inflammatory microenvironment targeted controlled-release drug delivery. The system is composed of exosome, active oxygen response bond modified mesoporous silica, PDA and an anti-inflammatory drug, the water solubility of natural medicinal compounds such as TB can be remarkably improved, the bioavailability can be improved, the effects of in-vivo and in-vitro specific targeted inflammation sites and efficient liver protection and hepatitis treatment can be achieved, the biotoxicity of TB is remarkably reduced, and the application prospect is broad. The compound is expected to be applied to safe and efficient acute liver injury treatment and prevention of natural medicinal compounds such as TB, so that a nanotechnology delivery strategy is provided for clinical application of other natural product monomers; the invention has important fundamental research significance and pre-clinical application value in the fields of accurate treatment, prevention and health care of acute hepatitis and acute liver injury.

This invention provides a method for treating a pulmonary arterial hypertension with reduced incident of side effect using a controlled release pharmaceutical composition of selexipag or its active metabolite, wherein the controlled release pharmaceutical composition of selexipag or its active metabolite following oral administration with an alcoholic beverage reduces incidence of at least one side effect associated with the selexipag or its active metabolite compared to the immediate-release dosage form comprising the same amount of the selexipag or active metabolite thereof.

The invention discloses a soluble microneedle composition for improving sleep and a microneedle and application of the soluble microneedle composition, and belongs to the technical field of medical care, the soluble microneedle composition comprises a needle tip section composition and a substrate composition, comprising 1%-70% of dexmedetomidine or a salt thereof, 1.5%-10% of glycerin, 1.5%-15% of mannitol and the balance of water. The substrate composition is an aqueous solution of a high-molecular compound. The soluble microneedle composition for improving sleep provided by the invention can prevent dexmedetomidine or a salt thereof from diffusing in a microneedle product, so that carried drugs are concentrated at a needle tip part, a technical support is provided for effective transmission of active components and accurate sustained and controlled release drug delivery, and quantitative drug delivery of dexmedetomidine or a salt thereof is realized.

The invention discloses a GSH (glutathione) response type nano-drug carrier as well as a preparation method and application thereof, the nano-drug carrier is a levofloxacin loaded BSA (bovine serum albumin) and PAMAM (polyamidoamine) compound, and is obtained by coupling BSA to a levofloxacin loaded PAMAM nano-drug by a disulfide bond-containing compound; the invention further discloses application of the levofloxacin loaded BSA and PAMAM compound in an antibiotic controlled release drug delivery system. According to the present invention, the drug can be effectively sealed, the non-specific release of the drug under the normal physiological condition can be prevented, the controllable release of the drug can be initiated in the presence of the GSH, the on-demand drug delivery can be achieved, and the drug delivery scheme can be optimized;

The invention belongs to the technical field of biomedical materials and targeted drug delivery systems, and discloses a targeted controlled-release drug delivery system based on a polymer nano-carrier and a preparation method thereof.The system is of a three-layer structure and comprises a core layer formed by taking polyvinyl alcohol as a matrix and used for efficiently entrapping a drug, and an outer layer formed by taking polyvinyl alcohol as a matrix and used for efficiently entrapping the drug; the shell layer formed by the polylactic acid-glycolic acid copolymer is used for providing structural stability and slow release capability, and the shell layer formed by the polyvinyl alcohol-hydroformylated glucan grafted copolymer is used for realizing microenvironment response release. And the surface of the shell layer is covalently modified with a tumor membrane targeting aptamer and a microenvironment response peptide, so that accurate recognition and local trigger release can be realized. The system has good particle size stability, responsive release ability and tumor cell targeted enrichment effect, and is suitable for efficient delivery and controlled release of various antitumor drugs.

This invention provides a controlled-release pharmaceutical composition containing indigo naturalis or its main active ingredient, a method for its preparation, and its application. The controlled-release pharmaceutical composition comprises microspheres, each microsphere containing the active ingredient and one or more pharmaceutically acceptable excipients. The active ingredient includes indigo naturalis, indigo, indirubin, or any combination thereof; the microspheres are coated with an enteric outer layer. The controlled-release pharmaceutical composition provided by this invention can alleviate the symptoms of inflammatory bowel diseases, especially ulcerative colitis, and can reduce or avoid the endocytosis of the active ingredient by intestinal macrophages, thereby reducing the impact on the patient's liver. It exhibits good stability, and the controlled-release pharmaceutical composition of this invention reduces side effects while maintaining therapeutic efficacy.

The invention provides composite hydrogel, photo-thermal response drug release composite hydrogel as well as a preparation method and application of the photo-thermal response drug release composite hydrogel, and belongs to the technical field of biomedical materials. The hydrogel is constructed by taking methylacryloyl gelatin as a matrix and combining lauric acid microspheres carrying an osteogenesis promoting drug baicalin, a reduced graphene oxide photothermal agent and a photoinitiator LAP. Under the irradiation of near-infrared light, the hydrogel can realize local mild temperature rise, induce the lauric acid microspheres to generate solid-liquid phase change, release the entrapped osteogenesis promoting drug as required, realize the synergistic effect of photothermal therapy and controlled release of the drug, and have a good osteogenesis repair effect. The hydrogel has good mechanical properties, biocompatibility and degradability, can be used for local treatment of bone defect parts, and effectively promotes regeneration and repair of oral and maxillofacial bone tissues. The invention provides a novel controllable and efficient treatment thought for bone tissue engineering and regenerative medicine.

The invention discloses an ultrasonic controlled-release drug balloon catheter which comprises a balloon with the outer surface coated with a drug coating and a catheter penetrating through the balloon, and the drug coating comprises a drug carrying layer, a hydrophilic layer located between the outer surface of the balloon and the drug carrying layer and an ultrasonic response layer located on the outer surface of the drug carrying layer; the ultrasonic response layer comprises the following components: at least one of PDMS (Polydimethylsiloxane), P (AAA) and P (NIPAM-co-AM); and an ultrasonic transducer is arranged on the catheter in the balloon. According to the ultrasonic controlled-release medicine balloon catheter, a'sandwich 'design of'hydrophilic bottom layer-medicine carrying layer-ultrasonic response layer' is adopted for the medicine coating on the surface of the balloon, and ultrasonic transducers with two or more frequencies are further arranged on the catheter in the balloon, so that the loss of the medicine coating in the conveying process can be avoided; transfer of the medicine from the balloon to the blood vessel at the treatment position is increased, the medicine can deeply permeate into the vascular tissue, vascular stenosis can be effectively inhibited for a long time, and the medicine utilization rate is effectively increased.

The present invention discloses a method of enabling a better and more controlled drug release from an oral administered pill and / or an oral delivery device by using gravity adding weight / high density content to secure that the pill / device decent through the stomach fluids and come in close contact with stomach and / or intestine tissue as it dissolves / releases the drug enabling a better controlled absorption / transfer of the drug to the blood stream.

The present disclosure relates to novel radiation-triggered controlled release drug compositions, and methods to make and use the radiation-triggered controlled release drug compositions. The radiation-triggered controlled drug release nanoparticle formulations may be used to achieve maximum bioavailability and minimum adverse effects of the chemo drugs in chemo radio combination therapy treatment of locally advanced solid tumors.

The present invention relates to a controlled release pharmaceutical composition comprising a decongestant, an acrylate copolymer, a cellulose derivative and a crosslinked acrylic acid polymer. The present invention provides an oral dosage form exhibiting a reproducible profile characterized by a controlled release of the decongestant over a period in excess of twelve hours and preferably at least 16 hours after oral administration. The invention further contemplates medical uses thereof. The release profile of the delivery system of the invention is highly reproducible and can be administered once daily, thus improving patient compliance.

The invention relates to the technical field of biology, and particularly discloses application of bilobalide B in plateau environment cognitive dysfunction protection. The application comprises the steps that a pharmaceutical composition containing bilobalide B is mixed with a low-concentration oxygen adaptation regulating agent to be used for regulating the pharmaceutical composition, and an intermediate product with the nerve protection enhancing effect is obtained; carrying out nano-carrier packaging and functionalization treatment on the intermediate product with the effect of enhancing neuroprotection, so as to realize brain-targeted controlled release of the drug to obtain a composite controlled release drug; the compound controlled-release medicine is administrated by adopting an administration dosage optimization method based on reinforcement learning, so that long-term prevention and improvement of cognitive impairment in a plateau environment are realized, and a final cognitive function protection effect is obtained; the whole formula is regulated and controlled by a nano controlled release technology, and all the components can be continuously released and uniformly distributed, so that the optimal balance between the drug effect and the safety is realized, and the problem of cognitive impairment caused by high altitude hypoxia is comprehensively improved.

The invention discloses a medicine patch and a medicine controlled release method, and belongs to the technical field of clinical medicine. The medicine patch comprises a substrate, a microneedle assembly arranged at the bottom of the substrate and a controlled release layer arranged at the top of the substrate, the controlled release layer can release medicine to the microneedle assembly layer at a first speed, then the microneedle assembly layer can penetrate through the cuticle of the skin and deliver the medicine to the corium layer of the skin, and diffusion of the medicine to the skin is completed; therefore, the medicine diffusion efficiency can be improved without depending on a chemical penetration enhancer, and skin irritation is avoided. And the controlled release layer can also control the first speed of releasing the medicine to the microneedle assembly layer according to the skin state, so that the effect of dynamically controlling the medicine release is realized.

The present invention relates to a controlled-release pharmaceutical composition comprising at least a controlled-release pharmaceutical dosage form containing EPAG, the controlled-release pharmaceutical composition being suitable for local injection into an affected area. The present invention also relates to a controlled-release pharmaceutical composition in powder form for preparing the pharmaceutical composition suitable for local injection, and a kit for preparing the pharmaceutical composition comprising an aqueous injection vehicle and a controlled-release dosage form or a mixture of controlled and immediate-release dosage forms containing EPAG, the pharmaceutical composition optionally including an excipient. The composition is useful for local injection in patients to improve stem cell homing and / or treat non-malignant hematological disorders, malignant hematological diseases, primary immunodeficiencies, autoimmune diseases, inborn errors of metabolism, and / or degenerative diseases / injuries.

Method for the production of cellulose molded bodies with controlled drug release comprising the following stages: a) Pulp is dispersed in an aqueous direct solvent for cellulose to form a cellulose slurry, b) In a separate process step, an organically modified nanoscale layered silicate or a nanoscale layered silicate pre-activated by ion exchange with potassium, calcium or aluminium ions is homogenized with an aqueous direct solvent for cellulose and partially or completely exfoliated by shear, added to the cellulose slurry and mixed with it, c) In a further separate process step, a composition of an active ingredient and a lipophilic matrix material for the active ingredient or an active ingredient-containing water-in-oil emulsion is stabilized by inorganic or organic thickeners and converted into a gel-like paste; this paste is also added to the cellulose slurry and mixed with it while stirring at temperatures up to 130 °C. d) Water is removed from the mixture until the cellulose is completely dissolved and e) The resulting spinning solution is formed into shaped bodies using a solution spinning process, then treated and dried.

The present invention provides a controlled-release pharmaceutical composition containing Indigo Naturalis or its main active ingredient, and a preparation method and use thereof. The controlled-release pharmaceutical composition includes micropellets. The micropellets include an active ingredient and one or more pharmaceutically acceptable excipients, the active ingredient includes Indigo Naturalis, indigo, indirubin, or any combination thereof; wherein the micropellets have an enteric outer layer. The controlled-release pharmaceutical composition provided by the present invention can alleviate the disease condition of inflammatory bowel disease, especially ulcerative colitis, and can reduce or avoid the phagocytosis of the active ingredient by intestinal macrophages, thereby reducing the effect on the patient's liver. The composition exhibits good stability and reduces side effects while maintaining therapeutic efficacy.

The invention provides a preparation method and application of a controlled-release pharmaceutical composition. Chitosan temperature-sensitive hydrogel and carboxymethyl-beta-cyclodextrin are used for improving the drug loading capacity, solubility and bioavailability of steroid drugs, especially ethinyloestradiol. Compared with a pure ethinylestradiol / carboxymethyl-beta-cyclodextrin inclusion compound, the controlled-release pharmaceutical composition provided by the invention has the advantages that the action time of the medicine can be prolonged, the stability of ethinylestradiol is improved, and the controlled-release capability of the medicine is enhanced. The preparation method disclosed by the invention is simple and convenient to operate and short in gelation time, and has a wide market application prospect.

The invention relates to the technical field of medical instruments, and particularly discloses an intelligent dressing system for chronic wounds. The system comprises a dressing body; a multi-mode sensing array; an edge calculation module; an adaptive intervention actuator; a healing process dynamic evaluation algorithm is built in the edge calculation module; the self-adaptive intervention actuator comprises a micro-pump controlled-release drug reservoir, a flexible heating element and a low-frequency electrical stimulation electrode. According to the system, closed-loop control for monitoring, evaluating and intervening is formed by integrating a healing process dynamic evaluation algorithm and a self-adaptive intervening actuator, an intervening strategy can be automatically adjusted according to the dynamic change of the wound state, instant and personalized nursing guidance is provided for a patient, and real-time dependence on remote medical support is remarkably reduced. A multi-dimensional feature extraction and machine learning classification method adopted by the system improves the objectivity and accuracy of wound state judgment.

The application discloses a controlled-release pharmaceutical composition and a preparation method and application thereof. The controlled-release pharmaceutical composition comprises a quick-release part and an enteric sustained-release part; the quick-release part comprises a first active ingredient, and the enteric sustained-release part comprises a second active ingredient and a sustained-release material; the first active ingredient or the second active ingredient is selected from racemic indobufen or S-indobufen or a pharmaceutically acceptable salt thereof; and the sustained-release material is selected from one or a combination of any number of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, xanthan gum, sodium alginate, sodium carboxymethyl cellulose, acrylic resin, carbomer or polyethylene oxide. The composition can realize once-a-day oral administration, reduces the frequency of drug taking of a patient, and improves the drug taking compliance of the patient; the preparation process is simple, short in time, low in energy consumption, and suitable for industrial production; the influence of food on product burst release is greatly reduced, the stimulation and adverse reactions of the product on the gastrointestinal tract are reduced, and in particular, the risk of gastric hemorrhage is reduced.

Provided herein are pharmaceutical compositions that include a pharmaceutically active agent, a cellulose nanocrystal or a cellulose nanofiber, a thermogelling biocompatible polymer, and a gelling agent. Such pharmaceutical compositions can be configured as a bioink suitable for 3D printing. Such pharmaceutical compositions are suitable for treating bone disorders, including osteoporosis. Methods of treating Paget's disease, treating or preventing cancer, treating or preventing an infectious disease, and treating or preventing a disorder through regenerative medicine are also provided.

The present application relates to a kind of targeting esophageal cancer's Mao Lan Su albumin nanoparticle and preparation method, application, belong to biopharmaceuticals.The Mao Lan Su albumin nanoparticle includes delivery carrier and the drug composition loaded in the delivery carrier, the drug is Mao Lan Su, the delivery carrier includes nucleic acid aptamer and albumin is made by coupling reaction.The particle size of the Mao Lan Su albumin nanoparticle is 100-200nm.The drug loading rate of the Mao Lan Su albumin nanoparticle is 11-19%, and the encapsulation efficiency is 69-81%.The present application utilizes thiol-modified nucleic acid aptamer to occur coupling reaction with albumin by linker molecule, generates delivery carrier, and utilizes the delivery carrier to load Mao Lan Su, to further improve the solubility and bioavailability of Mao Lan Su, so that Mao Lan Su reaches targeted drug delivery, the effect of slow-release drug, for the treatment of esophageal cancer, improve the efficacy of drug.

The invention belongs to the technical field of medical stents, and particularly relates to a drug-loaded ZIF8 surface modified polycaprolactone stent as well as a preparation method and application thereof. The polycaprolactone stent comprises a polycaprolactone stent body, and a bonding layer and a drug loading layer which sequentially wrap the polycaprolactone stent body, the drug loading layer comprises a drug and a zeolite imidazate framework material; the medicine is encapsulated in the zeolite imidazate framework material. The surface of the polycaprolactone scaffold body is sequentially wrapped with the bonding layer and the drug loading layer, so that ZIF8 is more easily deposited on the surface of the polycaprolactone scaffold body, the scaffold is endowed with biological activity through ZIF8 deposition modification, osteogenic differentiation of stem cells can be remarkably induced, and an antibacterial effect is achieved; in addition, the medicine is encapsulated in the ZIF8, so that the loading capacity of the medicine can be greatly improved, and the osteogenesis promoting activity of the stent can be remarkably enhanced and the burst release of the medicine can be reduced through controlled release of the medicine.

The invention discloses hydrogel microspheres for regulating an aging microenvironment as well as a preparation method and application of the hydrogel microspheres. The hydrogel microspheres are obtained by mixing hollow mesoporous silicon dioxide IL37-coated HMS coated with recombinant protein IL37 and nanoparticles Man-4OI-PLGA modified by mannose and loaded with 4OI when the hydrogel microspheres with pH response are prepared. The hydrogel can be dissociated in an acidic microenvironment of a degenerative tissue and release carried drugs, so that the biological activity of IL37 can be effectively protected, slow release of the drugs is realized, the residence time and treatment efficiency of IL37 at a focus part are remarkably improved, the stability of itaconic acid in a body can be effectively protected, and the treatment effect of the itaconic acid is improved. The itaconic acid can be accurately released at a focus part, and the enrichment efficiency of the itaconic acid in macrophages is greatly improved. The hydrogel provided by the invention meets the special requirements of small intervertebral disc space and high pressure on carrier mechanical strength, biocompatibility and controlled drug release, and has important significance on treatment of degenerative diseases.

Disclosed herein are polymeric implants and controlled release drug delivery systems to provide high drug loading and long-acting drug release. Provided herein are methods for making the same. Methods of administering pharmacologically active agents via the disclosed polymeric implants and controlled release drug delivery systems are also provided.

The invention discloses a quality detection method for the sustained-release performance of sustained-release pharmaceutical excipients. The method comprises the following steps: collecting and fitting the diffusion images of excipients to construct a three-dimensional model of excipient distribution, substituting the model into a sustained-release performance analysis model for colorimetric analysis, comprehensively analyzing the sustained-release performance of the excipients, and then constructing an excipient performance influence model to explore the joint action mechanism of the dissolution medium of the pharmaceutical excipients and the properties of the excipients on the sustained-release performance of the excipients, thereby ensuring the comprehensiveness of the data influence analysis and improving the detection work efficiency; through a sustained-release drug design model and based on the actual needs of drug application, a prefabricated drug of the sustained-release drug is designed, and then through a drug production verification model, the deviation of the excipient performance influence model is compared and analyzed, drug production verification is achieved and the model is optimized, thereby improving the accuracy of the sustained-release performance of the excipients of the prefabricated drug in the actual application process, ensuring the drug sustained-release effect of the sustained-release drug, and thus improving the drug production quality.

The application discloses a kind of polydopamine / drug nano composite particles and preparation method and application thereof.The polydopamine / drug nano composite particles in aqueous solution, using the synchronous process of alkaline drug molecule crystallization and dopamine oxidative polymerization, green synthesis nano drug.The polydopamine / drug nano composite particles of the application have: (1) high drug loading efficiency, simple preparation method; (2) have excellent active oxygen scavenging capacity; (3) response active oxygen controlled release drug; (4) the active oxygen of synthesis nano drug retains the activity of drug, such as nanofasudil nano drug can inhibit ROCK signal pathway; (5) good biocompatibility; can significantly reduce the ROS level in diabetic retinopathy model, reduce the expression of inflammatory factors, improve vascular leakage and inhibit neovascularization.The preparation process of the application is simple, the reaction condition is mild, and the biocompatibility is good, which provides a new nano drug delivery strategy for the treatment of diabetic retinopathy.